TY - JOUR
T1 - Phase II study of treatment for newly diagnosed multiple myeloma patients over 75 years old with alternating bortezomib/dexamethasone and lenalidomide/dexamethasone
T2 - The MARBLE trial
AU - Yokoyama, Akihiro
AU - Kada, Akiko
AU - Saito, Akiko M.
AU - Sawamura, Morio
AU - Komeno, Takuya
AU - Sunami, Kazutaka
AU - Takezako, Naoki
N1 - Publisher Copyright:
© 2019 by Okayama University Medical School.
PY - 2019
Y1 - 2019
N2 - Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate.
AB - Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate.
UR - http://www.scopus.com/inward/record.url?scp=85077202725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077202725&partnerID=8YFLogxK
M3 - Article
C2 - 31871340
AN - SCOPUS:85077202725
SN - 0386-300X
VL - 73
SP - 547
EP - 552
JO - Acta Medica Okayama
JF - Acta Medica Okayama
IS - 6
ER -